Dr. Arthur Moss answers the question: 'Cardiac Resynchronization Device?' — -- Question: What is a cardiac resynchronization device, and is it the same as a pacemaker? Answer:Well, in a way it's ...

Receipt of a cardiac-resynchronization therapy-defibrillator (CRT-D) offers long term benefit for patients with heart failure, reduced ejection fraction, and a widened QRS complex, according to a ...

Contemporary cardiac resynchronization therapy (CRT) devices are equipped with reliable and extensive diagnostic and memory features yielding full disclosure of the frequency, duration, and overall ...

We tested the hypothesis that prophylactic cardiac-resynchronization therapy in the form of biventricular stimulation with a pacemaker with or without a defibrillator would reduce the risk of death ...

BOSTON — Cardiac resynchronization therapy (CRT) seemed to improve 12-month clinical outcomes in patients with heart failure (HF) but without left bundle-branch block (LBBB) on their ...

Background Studies of cardiac resynchronization therapy in addition to an implantable cardioverter defibrillator in patients with mild to moderate congestive heart failure had not been shown to reduce ...

A pacemaker-like device restored heart function in a group of cancer survivors -- mostly women with breast cancer -- who had suffered from heart failure as a result of chemotherapy treatment, a study ...

Data Demonstrate Clinical and Economic Value of Underutilized Treatment for Heart Failure Patients at American Heart Association's Scientific Sessions 2014 MINNEAPOLIS and CHICAGO - Medtronic, Inc.

A meta-analysis by investigators from FDA of three major trials of cardiac resynchronization therapy (CRT) demonstrated that women have a reduced rate of heart failure (HF) and death with CRT at a ...

MINNEAPOLIS - Medtronic, Inc. today announced CE (Conformité Européenne) Mark receipt and the European launch of its newest cardiac resynchronization therapy-pacemaker, Viva® CRT-P. The Viva CRT-P is ...

The U.S. cardiac resynchronization therapy market was valued at $965.6 million in 2019, and is projected to reach $983.3 million by 2027, registering a CAGR of 4.9% from 2020 to 2027. Surge in ...